Evidence map›Paper›PMID 40432819›Full record

ArticleERJ open research2025

Deleterious effect of

Caterina Allegretta, Enza Montemitro, Maria Noemi Sgobba, Valeria Capurro, Emanuela Pesce, Fabiana Ciciriello, Gianfranco La Bella, Martina Rossito, Vanessa Tuccio, Fabio Arena and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Caterina AllegrettaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Enza MontemitroCystic Fibrosis Center, Specialistic Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Noemi SgobbaDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, Italy.
Valeria CapurroUOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Emanuela PesceUOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Fabiana CicirielloCystic Fibrosis Center, Specialistic Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Gianfranco La BellaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.ORCID https://orcid.org/0000-0003-3557-1439
Martina RossitoCystic Fibrosis Diagnostic Unit, Laboratory and Specialistic Pediatrics Departments, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Vanessa TuccioCystic Fibrosis Diagnostic Unit, Laboratory and Specialistic Pediatrics Departments, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Fabio ArenaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Tarini N A GunawardenaProgramme in molecular Medicine, The Hospital for Sick Children, Toronto, Canada.
Lorenzo GuerraDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, Italy.
Nicoletta PedemonteUOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Nazzareno CapitanioDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Claudia PiccoliDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Onofrio LaselvaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The triple cystic fibrosis transmembrane conductance regulator (CFTR) modulators combination elexacaftor/tezacaftor/ivacaftor (ETI) has been approved for people with cystic fibrosis (pwCF) bearing at least one Methods: We first tested the clinical exoproducts (EXO) of Results: We found that EXO variably decreased WT-, F508del- and ETI-dependent F508del-CFTR function and increased proinflammatory cytokines and reactive oxygen species (ROS) levels in a clinical strain-specific manner. Similarly, we observed a variable reduction of F508del-CFTR function in presence or absence of ETI and upregulation of proinflammatory cytokines and ROS levels. Interestingly, HNECs treated with EXO isolated from the corresponding donor and three different pwCF showed a variable reduction of ETI-dependent F508del-CFTR function mainly due to clinical strains with limited effect of patient background. Furthermore, we demonstrated that ETI pretreatment decreased the cytokines and ROS levels down to the levels of uninfected cells. Conclusion: These preclinical studies suggest that

Identifiers

PMID40432819
PMCPMC12107384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.